Publications by authors named "C Matsouka"
LaMMnO (M = Sr, Ca, (x = 0-0.5)) materials of the perovskite structure are synthesized by a co-precipitation method. They are subsequently investigated for their performance in a chemical looping process (fuel CH) using thermogravimetric analysis with simultaneous reaction.
View Article and Find Full Text PDFArterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- A Phase I clinical trial assessed the maximum tolerated dose (MTD) of WP1066 in recurrent glioblastoma (GBM) patients, determining the maximum feasible dose (MFD) to be 8 mg/kg without significant toxicities.
- Out of eight patients, common side effects included grade 1 nausea and diarrhea, with no treatment-related deaths; however, all patients experienced disease progression, with a median progression-free survival of 2.3 months.
- Immunological analyses showed WP1066 effectively suppressed p-STAT3 at doses starting from 1 mg/kg, indicating potential immune modulation, and a Phase II study is planned for newly diagnosed GBM patients.
Background: Vaccine Induced Thrombotic Thrombocytopenia (VITT) is a rare complication following ChAdOx1 (AstraZeneca) vaccination. Venous thrombosis in unusual sites such as splachnic or intracranial thrombosis, is the commonest manifestation.
Case Report: We report a 35-year-old male patient who presented with acute left leg ischemia and thrombocytopenia 11-days after vaccination requiring emergent thrombectomy.